Development of sensitive monoclonal antibody PMab-2 against rat podoplanin

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 34, Issue 6, 2015, Pages 396-403

  Oki, Hiroharu ^a,b   Honma, Ryusuke ^a,b   Ogasawara, Satoshi ^a   Fujii, Yuki ^a   Liu, Xing ^a,b   Takagi, Michiaki ^b   Kaneko, Mika K ^a   Kato, Yukinari ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PMAB 2; PODOPLANIN; UNCLASSIFIED DRUG; GP38 PROTEIN, RAT; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; PEPTIDE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; CELL DENSITY; CHO CELL LINE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KINETICS; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; ANIMAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; CRICETULUS; GENE EXPRESSION; GENETICS; HAMSTER; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; PROTEIN TERTIARY STRUCTURE; RAT; SYNTHESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; RECOMBINANT PROTEINS;

EID: 84951836296     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2015.0041     Document Type: Article

References (44)

1. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, and Kerjaschki D. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997; 151: 1141-1152
2. Gandarillas A, Scholl FG, Benito N, Gamallo C, and Quintanilla M. Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog 1997; 20: 10-18
3. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, and Tsuruo T. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003; 278: 51599-51605
4. Kaneko MK, Kato Y, Kitano T, and Osawa M. Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 2006; 378: 52-57
5. Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, and Yamaguchi Y. A platform of C-type lectin-like receptor CLEC-2 for binding o-glycosylated podoplanin and nonglycosylated rhodocytin. Structure 2014; 22: 1711-1721
6. Bertozzi CC, Schmaier AA, Mericko P, Hess PR, Zou Z, Chen M, Chen CY, Xu B, Lu MM, Zhou D, Sebzda E, Santore MT, Merianos DJ, Stadtfeld M, Flake AW, Graf T, Skoda R, Maltzman JS, Koretzky GA, and Kahn ML. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010; 116: 661-670
7. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, and Kerjaschki D. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999; 154: 385-394
8. Acton SE, Astarita JL, Malhotra D, Lukacs-Kornek V, Franz B, Hess PR, Jakus Z, Kuligowski M, Fletcher AL, Elpek KG, Bellemare-Pelletier A, Sceats L, Reynoso ED, Gonzalez SF, Graham DB, Chang J, Peters A, Woodruff M, Kim YA, Swat W, Morita T, Kuchroo V, Carroll MC, Kahn ML, Wucherpfennig KW, and Turley SJ. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity 2012; 37: 276-289
9. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, Wucherpfennig K, Turley S, Carroll MC, Sobel RA, Bettelli E, and Kuchroo VK. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011; 35: 986-996
10. Astarita JL, Cremasco V, Fu J, Darnell MC, Peck JR, Nieves-Bonilla JM, Song K, Kondo Y, Woodruff MC, Gogineni A, Onder L, Ludewig B, Weimer RM, Carroll MC, Mooney DJ, Xia L, and Turley SJ. The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture. Nat Immunol 2015; 16: 75-84
11. Acton SE, Farrugia AJ, Astarita JL, Mourao-Sa D, Jenkins RP, Nye E, Hooper S, van Blijswijk J, Rogers NC, Snelgrove KJ, Rosewell I, Moita LF, Stamp G, Turley SJ, Sahai E, and Reis e Sousa C. Dendritic cells control fibroblastic reticular network tension and lymph node expansion. Nature 2014; 514: 498-502
12. Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Lee JJ, Retzbach EP, Shen Y, Fatahzadeh M, Baredes S, Kalyoussef E, Honma M, Adelson ME, Kaneko MK, Kato Y, Young MA, Deluca-Rapone L, Shienbaum AJ, Yin K, Jensen LD, and Goldberg GS. Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget 2015; 6: 9045-9060
13. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, and Tsuruo T. Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004; 23: 8552-8556
14. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, and Quintanilla M. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005; 113: 899-910
15. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, and Osawa M. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 2005; 26: 195-200
16. Yuan P, Temam S, El-Naggar A, Zhou X, Liu D, Lee J, and Mao L. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006; 107: 563-569
17. Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K, and Osawa M. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006; 349: 1301-1307
18. Mishima K, Kato Y, Kaneko MK, Nakazawa Y, Kunita A, Fujita N, Tsuruo T, Nishikawa R, Hirose T, and Matsutani M. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol 2006; 111: 563-568
19. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, and Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006; 111: 483-488
20. Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, and Nishioka Y. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol 2013; 190: 6239-6249
21. Kunita A, Kashima TG, Ohazama A, Grigoriadis AE, and Fukayama M. Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol 2011; 179: 1041-1049
22. Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, and Bigner DD. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 2013; 132: 2339-2348
23. Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, and Zalutsky MR. Evaluation of antipodoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol 2010; 37: 785-794
24. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K, and Ochiai A. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008; 123: 1053-1059
25. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai K, Sasaki H, and Ochiai A. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res 2011; 71: 4769-4779
26. Schoppmann SF, Jesch B, Riegler MF, Maroske F, Schwameis K, Jomrich G, and Birner P. Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis 2013; 30: 441-446
27. Shindo K, Aishima S, Ohuchida K, Fujiwara K, Fujino M, Mizuuchi Y, Hattori M, Mizumoto K, Tanaka M, and Oda Y. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. Mol Cancer 2013; 12: 168
28. Inoue H, Tsuchiya H, Miyazaki Y, Kikuchi K, Ide F, Sakashita H, and Kusama K. Podoplanin expressing cancerassociated fibroblasts in oral cancer. Tumour Biol 2014; 35: 11345-11352
29. Hatakeyama K, Kaneko MK, Kato Y, Ishikawa T, Nishihira K, Tsujimoto Y, Shibata Y, Ozaki Y, and Asada Y. Podoplanin expression in advanced atherosclerotic lesions of human aortas. Thromb Res 2012; 129: e70-76
30. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger H, Banerjee D, and Baumal R. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999; 80: 569-578
31. Ogasawara S, Kaneko MK, Price JE, and Kato Y. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma 2008; 27: 259-267
32. Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K, and Fujita N. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One 2013; 8: e73609
33. Kato Y, and Kaneko MK. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep 2014; 4: 5924
34. Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M, and Kato Y. Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin. Monoclon Antib Immunodiagn Immunother 2015; 34: 174-180
35. Kaneko MK, Oki H, Ogasawara S, Takagi M, and Kato Y. Anti-podoplanin monoclonal antibody LpMab-7 detects metastatic legions of osteosarcoma. Monoclon Antib Immunodiagn Immunother 2015; 34: 154-161
36. Oki H, Ogasawara S, Kaneko MK, Takagi M, Yamauchi M, and Kato Y. Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin. Monoclon Antib Immunodiagn Immunother 2015; 34: 44-50
37. Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, and Kato Y. Development of a monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin. Monoclon Antib Immunodiagn Immunother 2015; 34: 318-326
38. Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, and Kato Y. Monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin. Monoclon Antib Immunodiagn Immunother 2015; 34: 310-317
39. Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, and Kaneko MK. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget, 2015; 6: 36003-36018
40. Watanabe M, Okochi E, Sugimoto Y, and Tsuruo T. Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies. Cancer Res 1988; 48: 6411-6416
41. Kaji C, Tsujimoto Y, Kato Kaneko M, Kato Y, and Sawa Y. Immunohistochemical examination of novel rat monoclonal antibodies against mouse and human podoplanin. Acta Histochem Cytochem 2012; 45: 227-237
42. Farr A, Nelson A, and Hosier S. Characterization of an antigenic determinant preferentially expressed by type I epithelial cells in the murine thymus. J Histochem Cytochem 1992; 40: 651-664
43. Kato Y. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathol 2015; 32: 3-11
44. Stein RA, Wilkinson JC, Guyer CA, and Staros JV. An analytical approach to the measurement of equilibrium binding constants: application to EGF binding to EGF receptors in intact cells measured by flow cytometry. Biochemistry 2001; 40: 6142-6154